和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCM 和黄医药

交易中 08-14 11:48:45 EDT

12.17

+0.01

+0.08%

最高12.19	最低12.11	成交量1,554
今开12.19	昨收12.16	日振幅0.66%
总市值21.23亿	流通市值12.66亿	总股本1.74亿
成交额1.89万	换手率0.00%	流通股本1.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCM","market":"US","secType":"STK","nameCN":"和黄医药","latestPrice":12.17,"timestamp":1786722228391,"preClose":12.16,"halted":0,"volume":1554,"delay":0,"changeRate":0.0008223684210526141,"floatShares":104000000,"shares":174433934,"eps":0.10095,"marketStatus":"交易中","change":0.01,"latestTime":"08-14 11:48:45 EDT","open":12.19,"high":12.19,"low":12.11,"amount":18904.972548,"amplitude":0.006579,"askPrice":12.24,"askSize":63,"bidPrice":12.06,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.10095,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786737600000},"marketStatusCode":2,"adr":1,"adrRate":5,"listingDate":1458187200000,"exchange":"NASDAQ","adjPreClose":12.16,"postHourTrading":{"tag":"盘后","latestPrice":12.16,"preClose":12.16,"latestTime":"19:34 EDT","volume":17,"amount":206.72,"timestamp":1786664047085,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.10107,"impliedVol":0.8203,"impliedVolPercentile":0.8327},"requestUrl":"/m/hq/s/HCM/tweets","defaultTab":"tweets","newsList":[{"id":"1171302218","title":"新闻稿：Braveheart Bio 宣布扩大规模首次公开募股完成，并完全行使承销商超额配股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1171302218","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171302218?lang=zh_cn&edition=full","pubTime":"2026-08-08 04:09","pubTimestamp":1786133340,"startTime":"0","endTime":"0","summary":"旧金山，2026年8月7日——Braveheart Bio, Inc.是一家临床阶段的生物制药公司，致力于开发针对肥厚型心肌病及其他严重心血管疾病的下一代疗法。该公司今日宣布，其扩大的首次公开募股已完成。此次发行总计24,437,500股普通股，每股发行价为18.00美元，且承销商已完全行使了购买额外3,187,500股的选择权。所有普通股均由Braveheart Bio提供。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMI","LU0289739343.SGD","BK4149","BK4007","LU0472753341.HKD","BK4533","LU0289961442.SGD","LU0154245673.USD","LU0069063385.USD","MADE","BK4531","LU0511384066.AUD","LU0154245756.USD","IE000M9KFDE8.USD","BK4588","LU0124676726.USD","LU2463526074.USD","BK4585","BK4567","LU0203345920.USD","LU0689626769.HKD","HCM","LU0057025933.USD","LU0203347892.USD","IPOS","BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657913306","title":"IDC：2025年中国AI增强HCM市场规模达2.41亿 同比增长505.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657913306","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657913306?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:38","pubTimestamp":1786081127,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CHAT","QTOC","AGIX","BK4585","AIPO","BK4007","BK4588","VTHR","HCM","BK4531","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657691332","title":"IDC：2025年中国AI增强HCM市场规模达2.41亿 同比增长505.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657691332","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657691332?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:38","pubTimestamp":1786081127,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国际数据公司最新发布的《中国AI增强的人力资本管理市场份额，2025》报告显示，2025年中国AI增强的人力资本管理市场规模达到2.41亿元人民币，同比增长505.7%。市场格局，头部厂商围绕智能化场景、平台与交付能力展开竞争IDC数据显示，2025年中国AI增强HCM市场竞争格局逐渐形成。IDC认为，用友代表了大型集团企业市场中平台型HCM厂商的发展路径，其优势集中体现在复杂组织管理、企业数据基础以及规模化交付能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","BK4007","BK4531","BK4585","VTHR","BK4588","AIPO","QTOC","CHAT","AGIX","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657155005","title":"【券商聚焦】申万宏源维持和黄医药（00013）买入评级 指呋喹替尼海外持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2657155005","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657155005?lang=zh_cn&edition=full","pubTime":"2026-08-05 14:38","pubTimestamp":1785911894,"startTime":"0","endTime":"0","summary":"金吾财讯 | 申万宏源发布研报指，和黄医药 2026年上半年收入2.78亿美元，同比增长0.2%，净利润为1,600万美元，同比下降96.5%，主因去年同期确认上海和黄药业处置收益，业绩符合预期。呋喹替尼海外市场持续拓展是核心亮点。研报预计，随着市场份额及医保覆盖范围扩大，其海外销售额有望进一步增长。考虑到呋喹替尼海外市场持续放量，申万宏源将26年的每股盈利预测从0.04美元上调至0.06美元，将27年预测从0.08美元上调至0.09美元，新增28年预测为0.10美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000166","KCE","00013","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656342224","title":"瑞银：降和黄医药(00013)目标价至29.5港元 续予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2656342224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656342224?lang=zh_cn&edition=full","pubTime":"2026-08-03 11:24","pubTimestamp":1785727484,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，和黄医药(00013)上半收入同比增0.2%，大致符合该行预期。肿瘤或免疫业务收入同比增长13%，高于该行预期；纯利1,590万美元，去年同期为4.55亿美元，主要是由于去年同期确认了出售上海医药合营的一次性收益。该行将阿斯利康的里程碑延后至2027年，并修正开支预测，导致2026年的每股盈测下调，而2027年的预测则已由6美仙上调至8美仙。该行将公司目标价由29.7港元下调至29.5港元，续予“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","00013","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656818342","title":"大行评级丨瑞银：微降和黄医药目标价至29.5港元，续予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2656818342","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656818342?lang=zh_cn&edition=full","pubTime":"2026-08-03 10:57","pubTimestamp":1785725823,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1587","EWH","HCM","BK1191","BK4007","00013","BK4588","BK4585","BK1588","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655362398","title":"和黄医药发布中期业绩 2026年上半年净利骤降96.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655362398","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655362398?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:06","pubTimestamp":1785506816,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司（简称“和黄医药”，00013.HK）7月30日晚间发布2026年中期业绩公告，上半年公司实现收入总额2.78亿美元，同比增长0.22%；归属于母公司所有者的净利润为1592.80万美元，同比下降96.50%，主要由于2025年同期包含出售上海和黄药业45%股权所得一次性收益4.16亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828677510.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828677510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","HCM","BK1588","BK1587","BK4007","BK4585","00013","BK4588","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655938258","title":"粤十数智、星宇股份、汉得信息递表港交所；和黄医药、先声药业、美图公司发布2026年中期业绩预告丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2655938258","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655938258?lang=zh_cn&edition=full","pubTime":"2026-07-31 07:01","pubTimestamp":1785452474,"startTime":"0","endTime":"0","summary":"｜2026年7月31日星期五｜NO.1粤十数智、星宇股份、汉得信息递表港交所据港交所7月29日披露，深圳粤十数智股份有限公司（以下简称粤十数智）、常州星宇车灯股份有限公司（以下简称星宇股份，SH601799）、上海汉得信息技术股份有限公司（以下简称汉得信息，SZ300170）已向港交所主板递交上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313827197718.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313827197718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300170","01357","BK1618","BK4585","IE00BPRC5H50.USD","LU2125910849.SGD","BK0188","601799","BK1613","BK4007","00013","BK1583","IE00B543WZ88.USD","LU0164939612.USD","SG9999001093.SGD","SG9999006597.SGD","LU2045819591.USD","BK1612","BK0231","BK0065","BK0070","BK4531","BK1095","LU2125910500.SGD","LU0082770016.USD","BK1191","BK0264","BK4588","LU0082770016.SGD","BK1609","IE00B5MMRT66.SGD","HCM","BK1587","LU0620787316.HKD","BK1588","IPOS","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874290","title":"和黄医药：2026年上半年净收益为1624万美元 同比降96.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874290","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655874290?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:42","pubTimestamp":1785411720,"startTime":"0","endTime":"0","summary":"7月30日，和黄医药（00013/HCM）发布2026年中期业绩，公司收入总额2.78亿美元，同比增长0.22%；净收益为1624万美元，同比减少96.43%；每股普通股基本盈利0.02美元。在管理层讨论与分析中提到，爱优特?和苏泰达?的强劲市场销售反映了公司商业团队针对中国市场监管指引变化所采取的有效措施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303826904289.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303826904289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK1191","BK4531","BK4588","HCM","BK1588","BK4585","00013","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655767578","title":"和黄医药：2026年上半年净收益1590万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655767578","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655767578?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:03","pubTimestamp":1785409407,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BK4531","BK4585","HCM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159471825","title":"财报前瞻｜和黄医药本季度营收暂无一致预测，机构观点偏中性观望","url":"https://stock-news.laohu8.com/highlight/detail?id=1159471825","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159471825?lang=zh_cn&edition=full","pubTime":"2026-07-24 05:02","pubTimestamp":1784840578,"startTime":"0","endTime":"0","summary":"和黄医药将在2026年07月30日发布最新财报，市场对营收和盈利的短期趋势仍在消化，关注核心商业化进展与研发资本开支节奏。目前未获得覆盖期内可用的一致预测及公司对本季度收入、毛利率、净利润或净利率、调整后每股收益的量化指引数据，相关机构仍待公司在财报披露时提供更清晰的展望。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜和黄医药本季度营收暂无一致预测，机构观点偏中性观望","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647636536","title":"和黄医药：上半财年业绩公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2647636536","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647636536?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:33","pubTimestamp":1782808380,"startTime":"0","endTime":"0","summary":"南财智讯6月30日电，和黄医药（00013.HK）公告，公司将于2026年7月30日召开董事会会议，批准截至2026年6月30日止六个月之中期业绩，并于同日发布。业绩发布后，管理层将于当日20:00（香港时间）举行英文网上直播简报会，并于2026年7月31日08:30（香港时间）举行中文（普通话）网上直播。相关简报文稿将提前上传至公司官网，视频回放亦将在简报会结束后上线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606303788357319.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303788357319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK4585","BK4588","HCM","BK4007","BK4531","00013","BK1587","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105047137","title":"新闻稿：Tenaya Therapeutics任命Eric Hyllengren为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1105047137","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105047137?lang=zh_cn&edition=full","pubTime":"2026-06-29 20:31","pubTimestamp":1782736275,"startTime":"0","endTime":"0","summary":"2026年6月29日，临床阶段生物技术公司Tenaya Therapeutics Inc宣布，任命Eric Hyllengren为首席财务官，自2026年7月13日起生效。履新后，Hyllengren将负责公司的财务战略、资本配置、投资者关系以及企业发展事务。Tenaya同时宣布，公司高级副总裁、财务负责人Hiro Higa将于2026年第三季度退休。Tenaya Therapeutics是一家临床阶段的生物技术公司，致力于一项宏伟使命：发现、开发和提供针对心脏病根本驱动因素的潜在治愈性疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BK4531","TNYA","BK4588","HCM","BK4585","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646842452","title":"和黄医药(00013.HK)将于2026年欧洲肿瘤内科学会胃肠道肿瘤大会公布凡瑞格拉替尼用于治疗肝内胆管癌的关键性II期研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2646842452","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646842452?lang=zh_cn&edition=full","pubTime":"2026-06-25 08:11","pubTimestamp":1782346297,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HCM","BK4007","BK4588","BK4585","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637361344","title":"和黄医药(00013)：股价刷新年内新低，何时迎变盘节点？","url":"https://stock-news.laohu8.com/highlight/detail?id=2637361344","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637361344?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:50","pubTimestamp":1779414620,"startTime":"0","endTime":"0","summary":"4月21日，CDE官网公示，和黄医药自主研发的醋酸索乐匹尼布片提交了用于治疗温抗体型自身免疫性溶血性贫血患者的新适应症上市申请。截至5月21日，和黄医药股价已跌破19港元。已进入明显低估区间5月20日盘中，和黄医药股价最低触及18.57港元，对应市值为161.93亿港元，刷新年内新低。在基本面支撑叠加严重低估情况下，和黄医药的短线上的变盘节点值得投资者期待。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","00013","BK4588","HCM","BK4531","BK1587","BK1588","BK4007","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637365831","title":"和黄医药(00013)将于美国临床肿瘤学会(ASCO)2026年年会上公布数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2637365831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637365831?lang=zh_cn&edition=full","pubTime":"2026-05-22 08:20","pubTimestamp":1779409235,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，和黄医药自主研发的化合物的数项研究的最新及更新后的数据将于2026年5月29日至6月2日在美国芝加哥召开的美国临床肿瘤学会年会上公布。该研究已达到主要终点，即根据RECIST 1.1标准经独立审查委员会评估的客观缓解率 。至数据截止日2025年10月8日，IRC评估的ORR为32.3% ，超过了预设的疗效阈值。这些数据支持了向中国国家药品监督管理局提交新药上市申请，该申请已于2025年12月获受理并纳入优先审评。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1587","BK1191","00013","HCM","BK4585","BK4007","BK4531","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631591630","title":"和黄医药(00013)：索乐匹尼布 (sovleplenib) 用于治疗温抗体型自身免疫性溶血性贫血患者的中国新药上市申请获受理并获纳入优先审评及突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2631591630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631591630?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:10","pubTimestamp":1777457421,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，索乐匹尼布用于治疗既往至少对糖皮质激素治疗反应不佳的成人温抗体型自身免疫性溶血性贫血的患者的新药上市申请已获中国国家药品监督管理局受理，并获纳入优先审评。索乐匹尼布于2026年3月获国家药监局纳入突破性治疗品种，用于治疗温抗体型自身免疫性溶血性贫血。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4007","BK1588","HCM","BK1587","IPOS","BK1191","BK4531","00013","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628758495","title":"李嘉诚弃中药押创新出状况？和黄医药11倍利润暴涨靠卖资产撑场，手握3款自研肿瘤药却困于转型局｜财报异动透视镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2628758495","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628758495?lang=zh_cn&edition=full","pubTime":"2026-04-18 21:15","pubTimestamp":1776518129,"startTime":"0","endTime":"0","summary":"作为首富李嘉诚医药版图的核心落子，和黄医药（00013.HK）日前同步披露的2025年年报与2026年一季度初步业绩报告，戳破了公司财务层面的纸面繁荣。2025年全年，公司归母净利润同比暴涨11倍，看似业绩迎来历史性突破，可超九成利润均来自出售资产的一次性收益，主营业务盈利几乎原地踏步。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604183709758454.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604183709758454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00001","HCM","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626975167","title":"和黄医药：将在AACR2026年会公布HMPL-A580等新药数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2626975167","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2626975167?lang=zh_cn&edition=full","pubTime":"2026-04-09 08:06","pubTimestamp":1775693177,"startTime":"0","endTime":"0","summary":"南财智讯4月9日电，和黄医药（00013.HK）发布自愿公告，公司自主研发的全球首创PI3K/PIKK-EGFR抗体靶向偶联药物（ATTC）HMPL-A580的临床前数据，以及索凡替尼联合疗法治疗小肠腺癌、阑尾癌及胰腺导管腺癌的Ib/II期研究更新结果，将于2026年4月17日至22日在美国圣迭戈举行的美国癌症研究协会（AACR）2026年年会上公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093698805369.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093698805369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK4531","BK4007","00013","BK4585","BK4588","BK1588","HCM","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624046576","title":"交银国际：4月港股有望筑底企稳 关注AI应用、智能驾驶等","url":"https://stock-news.laohu8.com/highlight/detail?id=2624046576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624046576?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:47","pubTimestamp":1775116050,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，港股3月主要扰动并非来自基本面，而是中东地缘不确定性，在缺乏企稳条件下，指数承压。港股有望从高波动震荡阶段缓步过渡至阶段性筑底企稳。另外，中东地缘不确定性若持续，高油价对内地能源板块仍形成直接盈利支撑，同时黄金受惠全球避险情绪与美元压力，维持战略性高配。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0228659784.USD","HSAI","HK0000306701.USD","LU0228367735.SGD","LU0259732245.USD","IE00B29SXG58.USD","LU0106959298.USD","LU0651946864.USD","BK1237","LU1439103000.SGD","LU1769817096.USD","BK1588","LU0471298777.SGD","LU0640798160.USD","LU0128522157.USD","HCM","LU0359202008.SGD","BK1191","LU0163747925.USD","SG9999011746.SGD","IE0008368742.USD","LU0287142896.SGD","LU0588546209.SGD","IE00B97KM107.HKD","LU0326950275.SGD","LU0328353924.USD","IE0008369823.USD","HK0000306685.HKD","BK4588","IE0032834883.USD","LU0315179316.USD","02525","HK0000320264.USD","IE00B067MR52.USD","HK0000320223.HKD","LU1102505762.USD","CIADY","LU2045819591.USD","IE00B031J352.USD","BK1597","LU0672654166.SGD","IE00B0169L03.USD","LU0385154629.USD","00013","LU0370786039.SGD","BK1587","300274","LU0823426480.USD","LU1023057109.AUD","02319","LU0543330483.HKD","BK1256","IE00B031HY20.USD","LU1769817179.HKD","IE0009570106.USD","00778","LU1102505929.USD","IE0031814852.USD","LU0307460666.USD","BK1553","LU1115378108.SGD","LU0072462343.USD","LU0320764755.SGD","LU0359201612.USD","LU0211977185.USD","SG9999002828.SGD","LU1048588211.SGD","LU0823426308.USD","LU0048580855.USD","LU1051768304.USD","LU1515016050.SGD","BK4585","BK1144","LU0029875118.USD","LU0251143458.SGD","LU0359201885.HKD","LU0650527681.SGD","BK1521","LU0348788117.USD","BK1589","BK1098","LU2125910500.SGD","NVDA","LU0173614495.USD","LU1224709979.USD","LU0594300419.USD","AVGO","LU0737861699.HKD","BK1147"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.0279},{"period":"1month","weight":0.0809},{"period":"3month","weight":-0.028},{"period":"6month","weight":-0.1762},{"period":"1year","weight":-0.24},{"period":"ytd","weight":-0.0878}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":-0.03068},{"month":2,"riseRate":0.4,"avgChangeRate":0.01065},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00847},{"month":4,"riseRate":0.454545,"avgChangeRate":0.024272},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.076728},{"month":6,"riseRate":0.636364,"avgChangeRate":0.064917},{"month":7,"riseRate":0.636364,"avgChangeRate":0.05138},{"month":8,"riseRate":0.454545,"avgChangeRate":0.010664},{"month":9,"riseRate":0.5,"avgChangeRate":-0.017634},{"month":10,"riseRate":0.5,"avgChangeRate":-0.007604},{"month":11,"riseRate":0.7,"avgChangeRate":0.110086},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016892}],"exchange":"NASDAQ","name":"和黄医药","nameEN":"Hutchison China Meditech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,HCM,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}